Abdrashitova G T

Abdrashitova G.T., Kotenko O.N., Serpik V.G., Yagudina R.I. 6907

For the first time in Russia, economic burden of chronic kidney disease on a national scale was determined The economic burden of chronic kidney disease was calculated based on the methodology of a special kind of pharmacoeconomic analysis, the «cost of illness» analysis. The analysis included both direct and indirect costs associated with the disease in question. In the course of the study, the cost of individual stages of chronic kidney disease per patient per year was determined. The most expensive stages were those, at which the patients received renal replacement therapy. At the same time, the cost of illness analysis based on the entire population carried out at the next stage revealed that most of the cost falls on the early stages of chronic kidney disease as a result of a significant number of patients at these stages. The cumulative economic burden of chronic kidney disease in Russia exceeded 451 billion rubles.

Abdrashitova G.T., Serpik V.G., Yagudina R.I. 5410

In the framework of the presented study, we have performed a pharmacoeconomic analysis of medical care for chronic kidney disease patients who need renal replacement therapy via peritoneal dialysis and hemodialysis. The study results demonstrates that the aggregate costs of peritoneal dialysis therapy, on the average, are lower than those of hemodialysis by 12 % due to the lower costs of treatment of the chronic kidney disease and renal replacement therapy related complications and lower indirect costs due to longer preservation of the capacity for work. Peritoneal dialysis demonstrated higher clinical effectiveness and lower aggregate costs and, as consequence, lower cost-utility ratio, i.e. demonstrated the advantages over hemodialysis.

Abdrashitova G.T., Babiy V.V., Komarov E.A., Pochuprina A.A., Serpik V.G., Ugrekhelidze D.T. 5313

Main presentations and educational seminars which took place during Annual European congress of International Society For Pharmacoeconomics and Outcomes Research (ISPOR) are covered

Abdrashitova G.T., Kulikov A.Y. 5106

This study includes pharmacoeconomic analysis of treatment of patients with severe and moderate ischemic stroke (NIHSS score > 12). The results of data search showed that today an evidential base for these patients treatment exists for cerebrolysin only. The analysis of «budget impact» showed that the transfer of one patient from the basic therapy to the combined therapy with cerebrolysin using gives saving of about 79703 rubles. Therefore the analysis of «costs-efficiency» ratio for the basic therapy with cerebrolysin using demonstrated it to be a dominated technology in comparison with the basic therapy only.

Abdrashitova G.T., Makarova E.I., Strunina (Rybchenko) Y.V., Ugrekhelidze D.T. 4911

Abstract: Main presentations and educational seminars which took place during Annual European congress of International Society For Pharmacoeconomics and Outcomes Research (ISPOR) are covered.

Abdrashitova G.T., Kulikov A.Y. 4629

A pharmacoeconomic study of cerebrovascular accident treatment with Cellex was conducted at the background of routine clinical practices in comparison with routine clinical practices only. It was found that in the first case the therapy is dominant in comparison with the second one as it shows better therapeutic effectiveness and is characterized by a lower cost-effectiveness ratio. It was also defined that transfer of one patient from routine clinical practices to Cellex treatment at the background of routine clinical practices is supported with the economy of 7 313 rubles.

Abdrashitova G.T., Babiy V.V., Komarov E.A., Pochuprina A.A., Serpik V.G., Ugrekhelidze D.T. 5313

Main presentations and educational seminars which took place during Annual European congress of International Society For Pharmacoeconomics and Outcomes Research (ISPOR) are covered

Abdrashitova G.T., Kotenko O.N., Serpik V.G., Yagudina R.I. 6907

For the first time in Russia, economic burden of chronic kidney disease on a national scale was determined The economic burden of chronic kidney disease was calculated based on the methodology of a special kind of pharmacoeconomic analysis, the «cost of illness» analysis. The analysis included both direct and indirect costs associated with the disease in question. In the course of the study, the cost of individual stages of chronic kidney disease per patient per year was determined. The most expensive stages were those, at which the patients received renal replacement therapy. At the same time, the cost of illness analysis based on the entire population carried out at the next stage revealed that most of the cost falls on the early stages of chronic kidney disease as a result of a significant number of patients at these stages. The cumulative economic burden of chronic kidney disease in Russia exceeded 451 billion rubles.

Abdrashitova G.T., Serpik V.G., Yagudina R.I. 5410

In the framework of the presented study, we have performed a pharmacoeconomic analysis of medical care for chronic kidney disease patients who need renal replacement therapy via peritoneal dialysis and hemodialysis. The study results demonstrates that the aggregate costs of peritoneal dialysis therapy, on the average, are lower than those of hemodialysis by 12 % due to the lower costs of treatment of the chronic kidney disease and renal replacement therapy related complications and lower indirect costs due to longer preservation of the capacity for work. Peritoneal dialysis demonstrated higher clinical effectiveness and lower aggregate costs and, as consequence, lower cost-utility ratio, i.e. demonstrated the advantages over hemodialysis.

Abdrashitova G.T., Kulikov A.Y. 5106

This study includes pharmacoeconomic analysis of treatment of patients with severe and moderate ischemic stroke (NIHSS score > 12). The results of data search showed that today an evidential base for these patients treatment exists for cerebrolysin only. The analysis of «budget impact» showed that the transfer of one patient from the basic therapy to the combined therapy with cerebrolysin using gives saving of about 79703 rubles. Therefore the analysis of «costs-efficiency» ratio for the basic therapy with cerebrolysin using demonstrated it to be a dominated technology in comparison with the basic therapy only.

Abdrashitova G.T., Makarova E.I., Strunina (Rybchenko) Y.V., Ugrekhelidze D.T. 4911

Abstract: Main presentations and educational seminars which took place during Annual European congress of International Society For Pharmacoeconomics and Outcomes Research (ISPOR) are covered.

Abdrashitova G.T., Kulikov A.Y. 4629

A pharmacoeconomic study of cerebrovascular accident treatment with Cellex was conducted at the background of routine clinical practices in comparison with routine clinical practices only. It was found that in the first case the therapy is dominant in comparison with the second one as it shows better therapeutic effectiveness and is characterized by a lower cost-effectiveness ratio. It was also defined that transfer of one patient from routine clinical practices to Cellex treatment at the background of routine clinical practices is supported with the economy of 7 313 rubles.